View Older Stories View More Recent Stories
-
Citizens Reiterates Market Outperform Rating on ProQR Therapeutics N.V. (PRQR)
-
Citizens Reiterates Market Outperform Rating on Terns Pharmaceuticals (TERN)
-
Lilly weight-loss pill could be FDA-approved by year-end
-
Citi bullish on Lilly as Orforglipron unlocks $40B+ obesity market
-
Citi Reiterates Buy Rating on Eli Lilly (LLY)
-
Citi on Hims and Hers (HIMS): 'If HIMS does end up partnering with LLY, in our view it would signal that HIMS is “throwing in the towel” on compounded GLP-1s'
-
Lilly offers weight-loss drugs in vials at a discount to fight competition
-
Citi Reiterates Buy Rating on Eli Lilly (LLY)
-
Lilly (LLY) to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
-
Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
-
Citi Reiterates Buy Rating on Eli Lilly (LLY)
-
Citi is 'aggressively' buying selloff in this pharma stock
-
Citi restarts coverage of Eli Lilly with Buy rating on increased tirzepatide forecasts
-
Citi Resumes Eli Lilly (LLY) at Buy
-
Eli Lilly partner BioAge files for US IPO
-
Citi on Hims and Hers (HIMS) Post Lilly (LLY) News: 'Single-dose Zepbound Vials a Shot Across the Bow for the Compounders'
-
Lilly launches vials of weight-loss drug Zepbound for as low as $399 a month
-
Selloff in MedTech stocks 'seems overdone': Citi
-
Lilly (LLY) Completes Acquisition of Morphic
-
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease
-
Eli Lilly & Co. (LLY) to Acquire Morphic (MORF) for $57/sh Cash or $3.2B
-
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
-
ResMed, Inspire Medical slump after Lilly's positive Zepbound data; Citi downgrades
-
Eli Lilly (LLY) stock climbs on gross margin beat, raised 2024 revenue outlook
-
Eli Lilly (LLY) PT Raised to $895 at Citi
-
Top pharma stocks to own in 2024 – Citi
-
Citi sees attractive buying opportunity in this beaten-down big pharma stock
-
Midday movers: Macy’s, Broadcom, Eli Lilly and more
-
Citi continue to see upside to Eli Lilly & Co.'s (LLY) 'already rich' valuation
-
Citi hikes Eli Lilly & Co. (LLY) price target on Incretin estimates
-
Eli Lilly (LLY) PT Raised to $675 at Citi
-
Dow Jones, Nasdaq, S&P 500 weekly preview: Better than feared Q2 results, worse than expected reactions
-
Today's most important downgrades
-
It's Good to Be Eli Lilly (LLY) in 2022 Says Citi Analyst
-
Lilly to Participate in Citi's 17th Annual BioPharma Conference
-
2 Reasons Why Citi Downgraded Merck (MRK) to Neutral Today, Opened a Negative Catalyst Watch
-
Pre-Open Stock Movers 09/29: (GREE) (AUVI) (LCID) Higher; (LFMD) (LSPD) (EQT) Lower (more...)
-
Eli Lilly (LLY) Stock Soars As Citi Upgrades to Buy Amid Recent Selloff in Shares
-
UPDATE: Citi Upgrades Eli Lilly (LLY) to Buy (correction)
-
Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities
-
Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of the Note Caps for
-
Eli Lilly & Co. (LLY) Announces Cash Tender Offer for for Up to $1.5B of its Notes
-
Lilly Announces Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities
-
Lilly to Participate in Citi's 16th Annual BioPharma Virtual Conference
-
Eli Lilly lifts 2020 profit forecast; coronavirus fuels stockpiling of its medicines
-
Elanco Animal Health (ELAN) Announces Upsizing and Pricing of Common Stock and Pricing of Tangible Equity Unit Offerings
-
Elanco Animal Health Announces Upsizing and Pricing of Common Stock and Pricing of Tangible Equity Unit Offerings
-
Elanco Animal Health (ELAN) Announces Common Stock, Tangible Equity Unit Offerings Associated with Financing Acquisition of Bayer's Animal Health Business
-
Elanco Animal Health Announces Common Stock and Tangible Equity Unit Offerings Associated with Financing Acquisition of Bayer’s Animal Health Business
-
Lilly (LLY) Announces Agreement to Acquire Dermira (DERM) for $18.75/Share in $1.1 Billion Deal
